The U.S. health regulator has granted accelerated approval to Sarepta Therapeutics’ first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder that almost always affects young boys. Sarepta said on Thursday the Food and Drug Administration had approved the treatment for children aged between 4 and 5 years who can walk. It was initially seeking approval for all DMD patients who can walk. The Associated Press has the story:
FDA OKs Gene therapy for Muscular Dystrophy
Newslooks- WASHINGTON (AP)
The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment’s ability to help boys with the inherited disease.
The Food and Drug Administration approval provides a new option for some patients with Duchenne muscular dystrophy, a rare muscle-wasting disease that causes weakness, loss of mobility and early death. It almost always affects males.
Drugmaker Sarepta Therapeutics said it would charge $3.2 million for the one-time treatment, slightly less than a $3.5 million gene therapy for hemophilia launched last year. Like most medicines in the U.S., the cost will be mostly paid by insurers — not patients — including private plans and government programs.
The FDA OK’d the treatment only for children ages 4 and 5, based on study results showing the therapy helped produce a protein needed for muscle growth, which is missing in boys with the condition. The gene therapy had been studied in children up to age 7.
Sarepta’s IV treatment delivers a replacement gene for the one that is mutated in boys with the condition.
“Today’s approval addresses an urgent unmet medical need and is an important advancement in the treatment of Duchenne muscular dystrophy, a devastating condition with limited treatment options,” said FDA’s Dr. Peter Marks, in a statement Thursday.
The FDA said the increase in protein seen with the therapy, Elevidys, is “reasonably likely to predict” a benefit in patients 4 to 5 years old, who don’t have other preexisting complications.
Patients, physicians and parents pushed for the therapy’s approval at a public meeting in April, sharing videos of boys running, riding bikes and doing sports and other activities, which they attributed to the treatment.
But FDA scientists detailed a long list of concerns with the company’s research, particularly a mid-stage study that the company submitted for FDA review. Overall, it failed to show that boys who received the therapy performed significantly better on measures like standing, walking and climbing than those who got a dummy treatment, although the results were better in younger kids.
Still, the FDA’s outside experts voted narrowly in favor of making the gene therapy available on a preliminary basis, noting the deadly nature of Duchenne and the risk of delaying a potentially beneficial treatment. The vote was non-binding, but the FDA often uses such recommendations to bolster its decisions.
The FDA advisers who backed the drug also seemed reassured that data from an ongoing 120-patient late-stage study is expected to wrap up late this year. If the results don’t show a benefit, the FDA has the option to revoke the approval.
The gene therapy was the latest treatment OK’d through the FDA’s fast-track route, which allows drugs to launch based on early results, before they’re confirmed to benefit patients. Until recently, the agency rarely used its power to pull drugs that failed to live up to their early promise.
The shortcut approach has come under increasing scrutiny from academic researchers, government watchdogs, and congressional investigators. But the FDA has also faced pressure from patient groups to use that route more aggressively for debilitating diseases, approving a string of recent treatments for Alzheimer’s, Lou Gehrig’s disease and other conditions with few treatment options.
Agency leaders have also pledged to use “regulatory flexibility” when considering drugs for rare diseases, such as Duchenne, which affects about 1 in 3,300 boys in the U.S. Most people with the condition do not live past their 20s.
Cambridge, Massachusetts-based Sarepta has won accelerated approval for threedrugs to treat different groups of Duchenne patients since 2016. None of those drugs have yet been confirmed to work; studies designed to secure full FDA approval are ongoing.
For the gene therapy, initial results from the company’s late-stage study are expected late this year, with more details released in 2024. Pfizer is among several competing drugmakers also working on gene therapies for the condition.
Sarepta’s treatment uses a disabled virus to ferry the replacement gene into cells. But because the gene for the missing dystrophin protein is so large, a smaller version of the gene is used. The FDA reviewers noted that the resulting protein is significantly different than any naturally occurring form and there is no evidence that it results in improved mobility or health for patients.
Regulators also worried about the potential consequences of giving patients an unproven gene therapy. Scientists believe there could be dangerous immune system reactions if someone is given a second virus-delivered therapy. That means patients who receive Sarepta’s gene therapy might be ineligible for future treatments that use viruses, FDA staff said.
